Telik's Proteasome Inhibitor Program Meets A Preclinical Development Milestone Telik, Inc. (Nasdaq: TELK) announced that its novel small molecule proteasome inhibitor program met a preclinical development milestone by demonstrating anticancer activity in preclinical models of human leukemia. The proteasome is an important cellular structure necessary for the growth and function of cancer cells and inhibition of the proteasome has been shown to promote cell cycle arrest and cancer cell death or apoptosis.
Source: www.medicalnewstoday.comMental Illness And Addiction Research Boosted By Large-Scale Investment The Centre for Addiction and Mental
Health (CAMH) is proud to announce a landmark investment of $15 million by the Canada Foundation for Innovation (CFI) into research that will propel the understanding, intervention, treatment and prevention of mental illness and addiction to the next level of excellence.
Source: www.medicalnewstoday.comFDA Requires Additional Information On DORIBAX For Treatment Of Hospital-Acquired Pneumonia Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) announced that the U.S. Food and Drug Administration (FDA) requires additional information before it will approve the company's New Drug Application (NDA) for DORIBAX(TM) (doripenem for injection) for the treatment of hospital-acquired pneumonia, also known as nosocomial pneumonia (NP), including ventilator-associated pneumonia (VAP).
Source: www.medicalnewstoday.comHead-to-Head Study Showed Prasugrel Statistically Superior To Clopidogrel In Reducing Recurrent Cardiovascular Events A new, pre-specified analysis of the landmark Phase III head-to-head TRITON-TIMI 38 study showed patients who took prasugrel for acute coronary syndromes (ACS) managed with an artery-opening procedure known as percutaneous coronary intervention (PCI) and had survived their first cardiov
Source: www.medicalnewstoday.com
# posted by Network @ 4:00 PM
